Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II International Thyroid Oncology Group trial Meeting Abstract
| Authors: | Haugen, B.; French, J.; Worden, F. P.; Konda, B.; Sherman, E. J.; Dadu, R.; Gianoukakis, A. G.; Wolfe, E. G.; Foster, N. R.; Bowles, D. W.; Wirth, L. J. |
| Abstract Title: | Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II International Thyroid Oncology Group trial |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 358s |
| Language: | English |
| ACCESSION: | WOS:000560368303020 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.6512 |
| Notes: | Meeting Abstract: 6512 -- Source: Wos |
